Efficacy and Safety of the Adjuvant Use of Probiotic Bacillus clausii Strains in Pediatric Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study.

Autor: Vázquez-Frias R; Departamento de Gastroenterología y Nutrición, Hospital Infantil de México Federico Gómez, National Health Institute, Mexico City, Mexico. rovaf@yahoo.com., Consuelo-Sánchez A; Departamento de Gastroenterología y Nutrición, Hospital Infantil de México Federico Gómez, National Health Institute, Mexico City, Mexico., Acosta-Rodríguez-Bueno CP; Servicio de Pediatría Mixta, Hospital Infantil de México Fedrico Gómez Instituto Nacional de Salud, Mexico City, Mexico., Blanco-Montero A; Clínica Pediatrica Pigüi, Mexico City, Mexico., Robles DC; Starmedica Chihuahua, Chihuahua, Mexico., Cohen V; Sanofi, Mexico City, Mexico., Márquez D; Sanofi, Mexico City, Mexico., Perez M 3rd; Sanofi, Frankfurt, Germany.
Jazyk: angličtina
Zdroj: Paediatric drugs [Paediatr Drugs] 2023 Jan; Vol. 25 (1), pp. 115-126. Date of Electronic Publication: 2022 Nov 16.
DOI: 10.1007/s40272-022-00536-9
Abstrakt: Objectives: Current irritable bowel syndrome (IBS) treatments have limited efficacy and probiotics like Bacillus clausii (B. clausii) were found to be effective in the management of several gastrointestinal disorders. This phase III trial assessed the efficacy and safety of adding B. clausii (four strains: O/C, N/R, SIN, T), versus placebo, to conventional treatment of pediatric IBS in Mexico.
Methods: Patients aged 6-17 years 11 months with IBS (Rome IV) for at least 2 months were randomized to receive either B. clausii (oral suspension, total dose 4 billion spores/day) or placebo once daily for 8 weeks. All patients also received conventional treatment. The primary endpoint was the difference in the proportion of patients with clinical improvements at Week 8 (Global Assessment Questions [GAQ]). Secondary endpoints included responders by Subject's Global Assessment of Relief for Children with IBS (SGARC); number/consistency of stools; abdominal distention/bloating; abdominal pain/intensity; and IBS behavior.
Results: 73.6% (95% confidence interval [CI] 67.3-80.0; B. clausii n = 129) and 78.5% (95% CI 72.5-84.4; placebo n = 130) of patients had symptom improvement (p = 0.8182). For Week 8 SGARC, 19.2% (B. clausii) and 20.9% (placebo) reported complete symptom relief. Stool evaluations, bloating, abdominal pain/intensity, and IBS behavior were similar between groups. Both treatments were well tolerated.
Conclusion: No significant differences in efficacy between B. clausii and placebo were demonstrated in addition to conventional treatment. The sample size calculation was based on an expected placebo/conventional treatment response of 30-40%. However, the actual treatment response observed was 80% and, thus, a study with larger population would be warranted. In addition, this study was conducted during the COVID-19 pandemic, when such controlled social conditions may have resulted in better diet, greater family stability, less psychological stress, and lower risk of infections exacerbating IBS, thereby improving symptoms in both groups.
Eudract Number: 2018-004519-31.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: